Alvotech 경영진

경영진 기준 점검 3/4

Alvotech CEO는 Lisa Graver, Mar2026 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $76.39K 가치에 해당하는 회사 주식의 0.007% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 각각 1.1 년과 5.5 년입니다.

핵심 정보

Lisa Graver

최고경영자

US$186.0k

총 보수

CEO 급여 비율	n/a
CEO 재임 기간	less than a year
CEO 지분 보유율	0.007%
경영진 평균 재임 기간	1.1yrs
이사회 평균 재임 기간	5.5yrs

최근 경영진 업데이트

Recent updates

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Apr 10

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Nov 20

Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues

Nov 09

Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers

Nov 06

Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%

May 25

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

May 28

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Apr 25

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Apr 03

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 24

CEO

Lisa Graver (53 yo)

less than a year

재임 기간

US$186,000

보수

Ms. Lisa Graver served as Chief Executive Officer of Alvogen, Inc. until December 2025. She was a Non-Executive Director of Alvotech from June 16, 2022 until March 31, 2025 and serves as its Chief Executiv...

리더십 팀

이름	직위	재임 기간	보수	지분
Vilhelm Wessman	Founder & Executive Chairman	7.3yrs	US$2.89m	데이터 없음
Lisa Graver	Chief Executive Officer	less than a year	US$186.00k	0.0068% $ 76.4k
Linda Jonsdottir	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Joseph McClellan	Chief Operating Officer	1.3yrs	데이터 없음	0.049% $ 556.1k
Benedikt Stefansson	Vice President of Investor Relations & Global Communications	no data	데이터 없음	데이터 없음
Tanya Zharov	General Counsel	3.3yrs	데이터 없음	0% $ 0
Sarah Macleod	Head of Global Communications	no data	데이터 없음	데이터 없음
Kathryn Gunnarsson	Senior Vice President of Global Talent & People Experience	1.3yrs	데이터 없음	데이터 없음
Anthony Maffia	Chief Quality & Regulatory Officer	2.3yrs	데이터 없음	데이터 없음
Balaji Prasad	Chief Strategy Officer	1.1yrs	데이터 없음	데이터 없음
Agne Pasko	Vice President & Head of Business Development	less than a year	데이터 없음	데이터 없음
Trisha Durant	Senior Vice President of Global Business Development and Commercial Operation	less than a year	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

53yo

평균 나이

경험이 풍부한 관리: ALVO의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.1 년) — 신규 팀일 수 있습니다.

이사회 구성원

이름	직위	재임 기간	보수	지분
Vilhelm Wessman	Founder & Executive Chairman	7.3yrs	US$2.89m	데이터 없음
Hjorleifur Palsson	Director	1.8yrs	US$149.00k	0.00075% $ 8.5k
Tomas Ekman	Non-Executive Director	7.3yrs	데이터 없음	데이터 없음
Arni Hardarson	Non-Executive Director	3.8yrs	데이터 없음	데이터 없음
Richard Davies	Independent Non-Executive Deputy Chairman	7.3yrs	US$307.00k	0.35% $ 3.9m
Ann Merchant	Independent Non-Executive Director	3.8yrs	US$241.00k	0.0068% $ 76.4k

5.5yrs

평균 재임 기간

59yo

평균 나이

경험이 풍부한 이사회: ALVO의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.5 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/19 14:43
종가	2026/04/17 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Alvotech는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Glen Santangelo	Barclays
Andrew Baum	Citigroup Inc
Peter Verdult	Citigroup Inc

Alvotech 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Lisa Graver to Step Down from the Board of Alvotech

Alvotech, Annual General Meeting, Jun 03, 2026

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech, Annual General Meeting, Jun 25, 2025

Alvotech Appoints Balaji V. Prasad as Chief Strategy Officer

Recent updates

Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player

Alvotech Reaffirms Earnings Guidance for 2026

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio

Lisa Graver to Step Down from the Board of Alvotech

Alvotech announced that it has received $100 million in funding

Alvotech, Annual General Meeting, Jun 03, 2026

Alvotech to Report Q3, 2026 Results on Nov 11, 2026

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Alvotech Reaffirms Earnings Guidance for 2025 and Provides Earnings Guidance for 2026

Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position

Alvotech Revises Earnings Guidance for the Full Year 2025

Alvotech Announces the Outcome of Expedited Infringement Paving Way for Manufacture and Market Entry of AVT06, Biosimilar to Eylea®?

Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®?, a Biosimilar to Simponi®? (golimumab), from the MHRA

Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Advanz Pharma Holdco Limited Announces European Medicines Agency Accepts Alvotech's Marketing Authorization Application for AVT23

European Medicines Agency Approves Alvotech's Proposed Biosimilar to Simponi®? (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech (NasdaqGM:ALVO) acquired Ivers-Lee AG.

Kashiv Biosciences Llc and Advanz Pharma Holdco Limited Announces Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair®? (Omalizumab)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea®? (aflibercept)

Alvotech has completed a Follow-on Equity Offering in the amount of SEK 750 million.

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

Alvotech, Annual General Meeting, Jun 25, 2025

Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%

Alvotech has completed a Follow-on Equity Offering in the amount of SEK 38.644416 million.

Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations

Alvotech Provides Revenue Guidance for the Year 2025

Teva Pharmaceuticals and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (Ustekinumab-Aekn) with Stelara®? (Ustekinumab)

Biosimilar Pipeline And R&D Capability Will Open New Markets

Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet

Alvotech Appoints Balaji V. Prasad as Chief Strategy Officer

Alvotech , Kashiv Biosciences LLC and Advanz Pharma Announces UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Alvotech to Report Fiscal Year 2024 Results on Mar 26, 2025

Teva Pharmaceuticals and Alvotech Announces the Availability of Selarsdi™? (Ustekinumab-Aekn) Injection in the U.S

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea®? (Aflibercept)

Alvotech and Teva Pharmaceuticals Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, A Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Alvotech to Report Q2, 2025 Results on Aug 14, 2025

Alvotech's Position In The Coming Biosimilar Gold Rush

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for Avt05, A Proposed Biosimilar to Simponi (Golimumab)

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva

Alvotech Initiates Confirmatory Patient Study for AVT16

Alvotech: Steady Progress Offers A Good Chance Of Upside

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts

Consensus revenue estimates increase by 15%

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Alvotech (NASDAQ:ALVO) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Consensus EPS estimates fall by 28%, revenue upgraded

Price target increased by 10% to US$16.17

Alvotech (NASDAQ:ALVO) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues miss analyst expectations

Alvotech Announces Executive Changes

Price target increased by 9.6% to US$12.33

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara